A new drug target for multiple epithelial tumors discovered by Compugen Compugen Ltd.

CGEN-671, a new drug target for multiple epithelial tumors discovered by Compugen Compugen Ltd. announced today the discovery and experimental validation of CGEN-671, a new drug target for multiple epithelial tumors. CGEN-671 can be a membrane splice variant of CD55, a known drug target for gastric cancer that monoclonal antibody therapeutics are in medical advancement by others medication information . The potential application of CGEN-671 as a drug target was predicted in initially silico by Compugen through the use of its Monoclonal Antibody Targets Discovery Platform; the predicted molecule was then validated in multiple epithelial tumors experimentally.